The evidence base for the efficacy of anti-TNFα agents in oral CD specifically is largely limited to case reports where an anti-TNFα has been employed primarily for management of coexistant intestinal disease, but several studies have demonstrated good efficacy of infliximab and adalimumab for other extraintestinal manifestations of CD (8). The gene discussed is TNF; the disease is intestinal disorder.